Dihexa is a synthetic peptide derived from angiotensin IV that is being investigated for neuroprotective and cognitive enhancement properties. It is not approved for human use and remains primarily a research compound.
Notes
Dihexa is not approved by the FDA or other major regulatory bodies for human use. Published human studies are extremely limited. This guide is for educational and harm-reduction purposes only and does not constitute medical advice. Users assume full responsibility for any use.
Dihexa is believed to work as a partial agonist at AT4 receptors and may enhance brain-derived neurotrophic factor (BDNF) signaling. It crosses the blood-brain barrier and is thought to promote neuronal growth, synaptic plasticity, and cognitive function through these pathways.
Dihexa is a small peptide that crosses the blood-brain barrier readily. Intranasal administration provides direct CNS access; subcutaneous routes undergo systemic absorption. Exact kinetics in humans are poorly characterized due to limited research.
Typical Dose
50–200 mcg per administration
Frequency
Once to twice daily
Administration
Intranasal, Subcutaneous injection
Half-Life
Unknown; likely minutes to hours based on peptide class